Aveo-Astellas kidney cancer drug is not recommended by FDA advisers

05/3/2013 | Yahoo

An FDA advisory panel voted 13-1 against recommending approval of Aveo Pharmaceuticals and Astellas Pharma's tivozanib as treatment for kidney cancer, citing inconsistent data from a clinical trial. The panel said another trial would be needed. Though disappointed with the decision, Aveo and Astellas said they would consult with the agency to address the advisers' concerns.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ